Skip to Main Content

Author Details

Andrew D Cherniack
Dana-Farber Cancer Institute
1984
121
62
PMIDPaper TitleJournal TitlePublished Year
36302897Velcrin-induced selective cleavage of tRNA<sup>Leu</sup>(TAA) by SLFN12 causes cancer cell death.Nat Chem Biol2023
36302897Velcrin-induced selective cleavage of tRNA<sup>Leu</sup>(TAA) by SLFN12 causes cancer cell death.Nat Chem Biol2023
37596911Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors.Pediatr Blood Cancer2023
37577567XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells.bioRxiv2023
37980405Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.Nat Commun2023
37463056Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Clin Cancer Res2023
37380777Cancer aneuploidies are shaped primarily by effects on tumour fitness.Nature2023
37247843Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.J Thorac Oncol2023
36996377Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma.JCO Precis Oncol2023
36542814Correction to "Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069".J Med Chem2023
37097610Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.Clin Cancer Res2023
37596911Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors.Pediatr Blood Cancer2023
37577567XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells.bioRxiv2023
37980405Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.Nat Commun2023
37247843Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.J Thorac Oncol2023
37380777Cancer aneuploidies are shaped primarily by effects on tumour fitness.Nature2023
37097610Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.Clin Cancer Res2023
36996377Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma.JCO Precis Oncol2023
37463056Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Clin Cancer Res2023
36542814Correction to "Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069".J Med Chem2023
34015129Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.Neuro Oncol2022
35708671Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.JAMA Oncol2022
36040373High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.Cancer Res2022
36040167Tangent normalization for somatic copy-number inference in cancer genome analysis.Bioinformatics2022
35872166Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer.Ann Oncol2022
35739269Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.Nat Med2022
36270630Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists <b>BAY-4931</b> and <b>BAY-0069</b>.J Med Chem2022
35365656Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.Nat Commun2022
36446043Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.JCO Precis Oncol2022
34015129Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.Neuro Oncol2022
34740862Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.J Thorac Oncol2022
35739269Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.Nat Med2022
35708671Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.JAMA Oncol2022
35365656Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.Nat Commun2022
36446043Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.JCO Precis Oncol2022
35872166Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer.Ann Oncol2022
36040373High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.Cancer Res2022
36040167Tangent normalization for somatic copy-number inference in cancer genome analysis.Bioinformatics2022
36270630Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists <b>BAY-4931</b> and <b>BAY-0069</b>.J Med Chem2022
34740862Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.J Thorac Oncol2022
33293374Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer.Clin Cancer Res2021
33845210SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.J Thorac Oncol2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
34272366Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.Nat Commun2021
34260938Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.Cell Rep2021
34140290Discovery and Features of an Alkylating Signature in Colorectal Cancer.Cancer Discov2021
33982016Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer.STAR Protoc2021
33926920<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.Cancer Discov2021
33247715Quantification of aneuploidy in targeted sequencing data using ASCETS.Bioinformatics2021
33293374Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer.Clin Cancer Res2021
  • 1 - 50 of 242

Recommended Authors

Huwate Yeerna
Moores Cancer Center, University of California
Career Start Year 2015
Number of shared co-authors 8
Gian Luca Negri
British Columbia Cancer Research Institute
Career Start Year 2013
Number of shared co-authors 6
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 8
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 49
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 5
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 16
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 9
Jonathan K Killian
From Foundation Medicine
Career Start Year 1999
Number of shared co-authors 7
Jan Koster
Amsterdam University Medical Centers location AMC
Career Start Year 1999
Number of shared co-authors 23
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 10
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 31
Agnes Viale
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 52
Yi-Mi Wu
University of Michigan Medical School ann arbor
Career Start Year 1995
Number of shared co-authors 21
Marbin Pineda
Center for Cancer Research, National Cancer Institute
Career Start Year 1995
Number of shared co-authors 3
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 17
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 60
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 2
Samuel Aparicio
University of British Columbia
Career Start Year 1993
Number of shared co-authors 26
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 30
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 68
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 17
Sean M Grimmond
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 28
Patrick Kwok-Shing Ng
The University of Texas MD Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 56
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 11
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 25
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 22
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 32

Collaborators

Matthew Meyerson
Broad Institute
Co-authored papers 49
Rehan Akbani
The University of Texas MD Anderson Cancer Center
Co-authored papers 26
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers 23
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 23
Peter W Laird
Van Andel Institute
Co-authored papers 23
Rameen Beroukhim
Co-authored papers 19
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 17
Hui Shen
Van Andel Institute
Co-authored papers 17
Reanne Bowlby
Co-authored papers 14
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 14
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 13
Galen F Gao
Broad Institute of Harvard and MIT
Co-authored papers 13
Christina Yau
University of California San Francisco
Co-authored papers 12
Chandra Sekhar Pedamallu
Broad Institute
Co-authored papers 12
Christopher C Benz
Buck Institute for Research on Aging
Co-authored papers 12
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers 12
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 11
Tara M Lichtenberg
Co-authored papers 11
Jaegil Kim
Co-authored papers 10
David A Wheeler
Baylor College of Medicine
Co-authored papers 10
Jean Claude Zenklusen
National Cancer Institute
Co-authored papers 10
Akinyemi I Ojesina
University of Alabama at Birmingham
Co-authored papers 9
Aviad Tsherniak
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard
Co-authored papers 9
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Co-authored papers 9
Francisca Vazquez
Broad Institute of MIT and Harvard
Co-authored papers 9
Steven E Schumacher
Co-authored papers 9
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 9
Roel G W Verhaak
Yale School of Medicine
Co-authored papers 8
Toshinori Hinoue
Co-authored papers 8
Francisco Vega
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
Release 1.2